IL-1β REPORT: Associated Diseases, Symptoms, Treatment Options

1. Pathophysiology: The Destructive Profile of IL-1β

Interleukin-1 Beta (IL-1β) is a highly potent, master pro-inflammatory cytokine produced primarily by activated macrophages, monocytes, and dendritic cells. Unlike many other cytokines, it is synthesized as an inactive precursor (pro-IL-1β). Its canonical activation follows a precise two-signal model.¹ The “priming” signal is initiated by receptors (e.g., TLRs or IL-1R itself) that activate the NF-κB pathway to transcribe pro-IL-1β and NLRP3 components.¹ The second “activation” phase involves intracellular protein assembly of the NLRP3 inflammasome with the adaptor ASC and effector caspase-1.¹’² Caspase-1 is then autocatalytically cleaved into its active form, which directly processes and matures pro-IL-1β into its active, highly destructive secreted form.¹’² Once secreted, IL-1β drives systemic inflammation, alters vascular permeability, and recruits immune cells to fuel localized or systemic tissue destruction.

2. Associated Diseases & Severe Complications